Results 201 to 210 of about 3,863,870 (310)

Forewarned Is Forearmed: The Single- and Dual-Brain Mechanisms in Detectors from Dyads of Varying Social Distance during Deceptive Outcome Evaluation. [PDF]

J Neurosci
Huang R, Gao X, Zhang C, Liu J, Zhang Y, Zhong Y, Chen Y, Wang H, Wei X, Liu Y.   +9 more
europepmc   +1 more source

Time Pressure Affects the Risk Preference and Outcome Evaluation. [PDF]

Int J Environ Res Public Health, 2023
Lin CJ, Jia H.
europepmc   +1 more source

Facial Bone Reconstruction Using both Marine or Non-Marine Bone Substitutes: Evaluation of Current Outcomes in a Systematic Literature Review [PDF]

, 2018
Marco Cicciù, Gabriele Cervino, Alan S. Herford, Fausto Famà, Ennio Bramanti, Luca Fiorillo, Floriana Lauritano, S. Sambataro, Giuseppe Troiano, Luigi Laino   +9 more
openalex   +1 more source

Tumor mutational burden as a determinant of metastatic dissemination patterns

Molecular Oncology, EarlyView.
This study performed a comprehensive analysis of genomic data to elucidate whether metastasis in certain organs share genetic characteristics regardless of cancer type. No robust mutational patterns were identified across different metastatic locations and cancer types.
Eduardo Candeal, Andrea Moreno‐Manuel, Miguel Salvadó‐Pertierra, Cristina Santos‐Vivas, Rebeca Sanz‐Pamplona   +4 more
wiley   +1 more source

Nose Obstruction Symptom Evaluation Scale Outcomes in Covid 19 Patients in the Turkish Population and Prognostic Factors Affecting the Scale

, 2021
Ayşe Rezan Çeçen, Cem Bayraktar, Abdulkadir Özgür, Gökhan Akgül, Özgür Günal, Mehmet Eser Sancaktar, Merve Mutlu   +6 more
openalex   +2 more sources

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

Molecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat, Aslihan Kucuk, Omer Erdogan, Samed Ozer, Bensu Kozan, Tugba Cuceli, Erkan Gumus, Evrim Cevik, Ozge Cevik   +8 more
wiley   +1 more source

Does "the different study period" influence outcome evaluation? [PDF]

J Chin Med Assoc
Li YT, Chang WH.
europepmc   +1 more source

The PI3Kδ inhibitor roginolisib (IOA‐244) preserves T‐cell function and activity

Molecular Oncology, EarlyView.
Identification of novel PI3K inhibitors with limited immune‐related adverse effects is highly sought after. We found that roginolisib and idelalisib inhibit chronic lymphocytic leukemia (CLL) cells and Treg suppressive functions to similar extents, but roginolisib affects cytotoxic T‐cell function and promotion of pro‐inflammatory T helper subsets to a
Elise Solli, Alessio Bevilacqua, Mathias Wenes, Denis Migliorini, Lars van der Veen, Sigrid S Skånland, Giusy Di Conza, Kjetil Taskén   +7 more
wiley   +1 more source

"Young Care": A Community-Based Intervention to Transform Youth Mindsets on Elder Care in Thailand-Program Development and Outcome Evaluation. [PDF]

Int J Environ Res Public Health
Wongkongdech R, Puangpronpitag D, Srisaknok T, Tudpor K, Turnbull N, Chanthamath S, Wongkongdech A.   +6 more
europepmc   +1 more source

Correlation of the differential expression of PIK3R1 and its spliced variant, p55α, in pan‐cancer

Molecular Oncology, EarlyView.
PIK3R1 undergoes alternative splicing to generate the isoforms, p85α and p55α. By combining large patient datasets with laboratory experiments, we show that PIK3R1 spliced variants shape cancer behavior. While tumors lose the protective p85α isoform, p55α is overexpressed, changes linked to poorer survival and more pronounced in African American ...
Ishita Gupta, Yang Song, Madeleine Ndahayo, Anirudh Saxena, Theresa Guo, Dylan Z. Kelley, Jessica Gore, Andrew Hennigan, Alexa Anderson, John C. Papadimitriou, Daria A. Gaykalova   +10 more
wiley   +1 more source